Average payments could range between $6,000 to $165,000 - or more.
BTK inhibitor monotherapy is foundational across several B-cell malignancies, with newer, more selective agents designed to preserve efficacy while improving tolerability relative to first-in-class ...
KARK Little Rock on MSN
Cancer survivor shares difficult journey of healing after diagnosis in hopes of inspring others
One moment changed Lonetta Bradford’s life forever.
The world’s most common herbicide is driving a wedge between Make America Healthy Again activists and their champions in the Trump administration. Tensions within the MAHA coalition are straining ...
Key opportunities in the B-cell inhibitors market for non-oncology diseases include the rising demand for targeted immunomodulatory therapies, driven by increasing autoimmune disorder prevalence.
T cell lymphomas are notoriously difficult to treat because immunotherapy, despite being one of the most effective therapies for treating cancer, can't easily distinguish cancerous T cells from ...
Wistar Institute scientists have designed a two-vaccine approach that not only targets the tumors’ unique molecular identity ...
CHICAGO — Each year around St. Patrick’s Day, a group of supporters known as “shave-ees” ditches their locks to raise ...
Ipsen is withdrawing tazemetostat from all markets following signals of secondary hematologic malignancies observed in SYMPHONY-1 evaluating tazemetostat plus lenalidomide/rituximab versus ...
The reality star was truly taken aback by SeaWorld's latest attraction ...
An estimated 50% of sterile medical devices in the U.S. are treated with ethylene oxide. It is also a known carcinogen.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results